1. United States of America Stocks

  2. •

    Healthcare

  3. •

    Medical - Diagnostics & Research
Insight Molecular Diagnostics Inc.

Insight Molecular Diagnostics Inc.

IMDX
Insight Molecular Diagnostics Inc.US flagNASDAQ Capital Market
2.89
USD
-0.12
- -
94.57MMarket Cap

Total Valuation

Insight Molecular Diagnostics Inc. carries a market capitalization of 94.57M, placing it among publicly traded companies globally. Its enterprise value stands at 177.34M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap94.57M
Enterprise Value177.34M

Share Statistics

Insight Molecular Diagnostics Inc. currently has 32.62M shares outstanding.

Shares Outstanding32.62M
Owned by Insiders (%)N/A
Owned by Institutions (%)N/A

Valuation Ratios

The price-to-sales ratio is 119.56, and the price-to-book ratio stands at -9.04.

PE RatioN/A
PS Ratio119.56
PB Ratio-9.04
P/TBV Ratio-9.04
P/FCF Ratio-8.62
P/OCF Ratio-7.37

Enterprise Valuation

EV / Sales106.19
EV / EBITDAN/A
EV / EBITN/A
EV / FCFN/A

Financial Position

Insight Molecular Diagnostics Inc. maintains a current ratio of 2.00, meaning it holds 2.0x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is -12.32, indicating conservative leverage, while an interest coverage ratio of -353.02 demonstrates limited ability to service its debt obligations.

Current Ratio2.00
Quick Ratio1.74
Debt / Equity-12.32
Debt / EBITDA-0.08
Interest Coverage-353.02

Financial Efficiency

Return on Equity (ROE)N/A
Return on Assets (ROA)-123.46
Return on Invested Capital (ROIC)N/A
Return on Capital Employed (ROCE)N/A
Revenue Per EmployeeN/A
Employee CountN/A
Inventory Turnover1.92

Stock Price Statistics

Insight Molecular Diagnostics Inc.'s stock has declined approximately -50.93379% over the past 52 weeks. The 50-day moving average sits at 3.86, while the 200-day moving average is 4.93.

Beta (5Y)N/A
52-Week Price Change-50.93379%
50-Day Moving Average3.86
200-Day Moving Average4.93
Average Volume (20 Days)N/A

Income Statement

Over the trailing twelve months, Insight Molecular Diagnostics Inc. generated 1.67M in revenue and converted that into -49.36M in net income, yielding earnings per share of -1.46. EBITDA reached -34.60M, while operating income came in at -37.04M.

Revenue1.67M
Gross Profit807,000.00
Operating Income-37.04M
Pretax Income-49.36M
Net Income-49.36M
EBITDA-34.60M
EBIT-37.04M
Earnings Per Share (EPS)-1.46

Balance Sheet

Insight Molecular Diagnostics Inc. holds 17.76M in cash and equivalents against 2.63M in total debt, resulting in a net debt position of -17.76M. Total book value stands at -21.30M, with working capital of 10.26M providing operational flexibility.

Cash & Cash Equivalents17.76M
Total Debt2.63M
Net Debt-17.76M
Equity (Book Value)-21.30M
Book Value Per Share-0.65
Working Capital10.26M

Cash Flow

Insight Molecular Diagnostics Inc. produced -27.08M in operating cash flow over the past twelve months. After subtracting -3.92M in capital expenditures, free cash flow totaled -31.00M - equivalent to -0.92 per share.

Operating Cash Flow-27.08M
Capital Expenditures-3.92M
Free Cash Flow-31.00M
FCF Per Share-0.92

Margins

Insight Molecular Diagnostics Inc. operates with a gross margin of 48.32, reflecting its pricing power and cost economics. The operating margin of -2,217.90 and net profit margin of -2,955.63 provide insight into operational efficiency.

Gross Margin48.32
Operating Margin-2,217.90
Pretax Margin-2,955.63
Profit Margin-2,955.63
EBITDA Margin-2,071.62

Dividends & Yields

Dividend Per ShareN/A
Dividend YieldN/A
Payout RatioN/A
Shareholder Yield-12.35
FCF Yield-11.60

Stock Splits

Insight Molecular Diagnostics Inc.'s most recent stock split took place on July 25, 2023 with a 20:1 split ratio.

Last Split Date7/25/2023
Split Ratio20:1

Scores

Insight Molecular Diagnostics Inc. posts an Altman Z-Score of -21.20, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.

Altman Z-Score-21.20